Edition:
United Kingdom

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

2.80USD
19 Jan 2018
Change (% chg)

$-0.30 (-9.68%)
Prev Close
$3.10
Open
$3.10
Day's High
$3.10
Day's Low
$2.60
Volume
100,267
Avg. Vol
20,180
52-wk High
$5.45
52-wk Low
$2.00

Select another date:

Thu, Dec 21 2017

BRIEF-Ambrx And Tracon Pharma Announce Commercialization Agreement For TRC105 In China

* AMBRX AND TRACON PHARMACEUTICALS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR TRC105 IN CHINA

BRIEF-Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara

* Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget

BRIEF-Tracon Pharma reports third quarter financial results

* Tracon Pharmaceuticals reports third quarter financial results and provides corporate update

BRIEF-683 Capital Management reports 5.4 pct passive stake in Tracon Pharmaceuticals

* 683 Capital Management Llc reports 5.4% passive stake in Tracon Pharmaceuticals Inc as of Sept 18, 2017 - SEC filing‍​ Source text: [http://bit.ly/2yb8Zbn] Further company coverage:

BRIEF-Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B traxar study of TRC105 and Inlyta in renal cell carcinoma

* Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B Traxar study of TRC105 and Inlyta in renal cell carcinoma

BRIEF-Tracon Pharmaceuticals files for offering of up to $14.33 mln of co's common stock‍​

* Files for offering of up to $14.33 million of co's common stock‍​ - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Tracon Pharmaceuticals announces positive results for phase 1/2 trial of TRC105 and Nexavar

* Tracon Pharmaceuticals announces positive results from National Cancer Institute Phase 1/2 trial of TRC105 and Nexavar in Hepatocellular cancer published in Clinical Cancer Research

BRIEF-Tracon Pharmaceuticals qtrly net loss per share $0.40

* Tracon Pharmaceuticals reports second quarter financial results and provides corporate update

BRIEF-Santen and Tracon announce initiation of a phase 2a study of drug for the treatment of wet age-related macular degeneration

* Santen and Tracon announce initiation of a phase 2a study of DE-122 for the treatment of wet age-related macular degeneration

Select another date: